1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation
3. Executive Summary
4. Global Axial Spondyloarthritis Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Advancement/Recent Development
4.4. Regulatory Framework
4.5. Porters Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
5. Global Axial Spondyloarthritis Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Commercialized Therapies
5.2.1.1. Anti-tumor Necrosis Factor Therapy (TNF)
5.2.1.2. Anti-Interleukin Therapy (IL)
5.2.1.3. Anti-Janus Kinase Therapy (JAK)
5.2.2. By Potential Pipeline Products
5.2.2.1. Anti-Janus Kinase Therapy (JAK)
5.2.2.2. Anti-Interleukin (IL)-17 Therapy
5.2.2.3. Other
5.2.3. By Indication
5.2.3.1. Ankylosing Spondylitis
5.2.3.2. Non-Radiographic Axial Spondylitis
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. The Asia Pacific
5.2.4.4. Latin America
5.2.4.5. The Middle East and Africa
6. North America Axial Spondyloarthritis Market
6.1. Market Size & Forecast by Value, 2018-2028
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Commercialized Therapies
6.2.2. By Potential Pipeline Products
6.2.3. By Indication
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada
7. Europe Axial Spondyloarthritis Market
7.1. Market Size & Forecast by Value, 2018-2028
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Commercialized Therapies
7.2.2. By Potential Pipeline Products
7.2.3. By Indication
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. United Kingdom
7.2.4.3. Italy
7.2.4.4. France
7.2.4.5. Spain
7.2.4.6. Rest of Europe
8. The Asia Pacific Axial Spondyloarthritis Market
8.1. Market Size & Forecast by Value, 2018-2028
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Commercialized Therapies
8.2.2. By Potential Pipeline Products
8.2.3. By Indication
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia Pacific
9. Latin America Axial Spondyloarthritis Market
9.1. Market Size & Forecast by Value, 2018-2028
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Commercialized Therapies
9.2.2. By Potential Pipeline Products
9.2.3. By Indication
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Mexico
9.2.4.3. Rest of Latin America
10. The Middle East & Africa Axial Spondyloarthritis Market
10.1. Market Size & Forecast by Value, 2018-2028
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Commercialized Therapies
10.2.2. By Potential Pipeline Products
10.2.3. By Indication
10.2.4. By Country
10.2.4.1. Brazil
10.2.4.2. Mexico
10.2.4.3. Rest of Latin America
11. Competitive Landscape
11.1. List of Key Players and Their Offerings
11.2. Market Share Analysis, 2021
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Development (Merger, Acquisition, Partnership.)
12. Impact of Covid-19 on Global Biomass Briquettes Industry
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
13.1. AbbVie Inc.
13.2. Amgen Inc.
13.3. Bristol-Myers Sqiubb Company
13.4. Eli Lilly and Company
13.5. Johnson & Johnson Services Inc.
13.6. Kyowa kirin Co
13.7. Merck & co
13.8. Novartis International AG
13.9. Pfizer Inc
13.10. Takeda Pharmaceutical Company
13.11. USB S.A
13.12. FunPep Co., Ltd
14. Key Strategic Recommendations
*Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable